Inhibition of the epidermal growth factor receptor in bladder cancer cells treated with the DNA-damaging drug etoposide markedly increases apoptosis

BJU International

Volumn 99, Issue 1, 2007, Pages 196-201

  Munk, Mathias ^a   Memon, Ashfaque Ahmed ^a   Nexo, Ebba ^a   Sorensen, Boe Sandahl ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Apoptosis; Cell survival; DNA damaging chemotherapy; EGF; Epidermal growth factor receptor; VP16 (etoposide)

Indexed keywords

CASPASE; CASPASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ETOPOSIDE; GEFITINIB; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; Z VAD;

ANIMAL CELL; APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER SURVIVAL; CONCENTRATION RESPONSE; DNA DAMAGE; DRUG MECHANISM; ENZYME ACTIVITY; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; RAT; WESTERN BLOTTING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; ETOPOSIDE; HUMANS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 33845476894     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06510.x     Document Type: Article

References (30)

1. Stein JP, Grossfeld GD, Ginsberg DA et al. Prognostic markers in bladder cancer: a contemporary review of the literature. J Urol 1998; 160: 645-59
2. Joel S. The clinical pharmacology of etoposide: an update. Cancer Treat Rev 1996; 22: 179-221
3. Tada Y, Wada M, Migita T et al. Increased expression of multidrug resistance-associated proteins in bladder cancer during clinical course and drug resistance to doxorubicin. Int J Cancer 2002; 98: 630-5
4. Sorensen BS, Torring N, Bor MV, Nexo E. The DNA damaging agent VP16 induces the expression of a subset of ligands from the EGF system in bladder cancer cells, whereas none of the four EGF receptors are induced. Mol Cell Biochem 2004; 260: 129-35
5. Holbro T, Civenni G, Hynes NE. The ErbB receptors and their role in cancer progression. Exp Cell Res 2003; 284: 99-110
6. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19: 183-232
7. Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997; 16: 1647-55
8. Battle TE, Frank DA. The role of STATs in apoptosis. Curr Mol Med 2002; 2: 381-92
9. Lin J, Adam RM, Santiestevan E, Freeman MR. The phosphatidylinositol 3′-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells. Cancer Res 1999; 59: 2891-7
10. Schlessinger J. New roles for Src kinases in control of cell survival and angiogenesis. Cell 2000; 100: 293-6
11. Silva CM. Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis. Oncogene 2004; 23: 8017-23
12. Popov Z, Gil-Diez-De-Medina S, Ravery V et al. Prognostic value of EGF receptor and tumor cell proliferation in bladder cancer: therapeutic implications. Urol Oncol 2004; 22: 93-101
13. Thogersen VB, Sorensen BS, Poulsen SS, Orntoft TF, Wolf H, Nexo E. A subclass of HER1 ligands are prognostic markers for survival in bladder cancer patients. Cancer Res 2001; 61: 6227-33
14. Memon AA, Sorensen BS, Melgard P, Fokdal L, Thykjaer T, Nexo E. Expression of HER3, HER4 and their ligand heregulin-4 is associated with better survival in bladder cancer patients. Br J Cancer 2004; 91: 2034-41
15. Wakeling AE. Inhibitors of growth factor signalling. Endocr Relat Cancer 2005; 12: S183-7
16. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-39
17. Dominguez-Escrig JL, Kelly JD, Neal DE, King SM, Davies BR. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer. Clin Cancer Res 2004; 10: 4874-84
18. Nutt JE, Lazarowicz HP, Mellon JK, Lunec J. Gefitinib ('Iressa', ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2. Br J Cancer 2004; 90: 1679-85
19. Schooler K, Wiley HS. Ratiometric assay of epidermal growth factor receptor tyrosine kinase activation. Anal Biochem 2000; 277: 135-42
20. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med 2002; 53: 615-27
21. Ciardiello F, Caputo R, Bianco R et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000; 6: 2053-63
22. Friedmann B, Caplin M, Hartley JA, Hochhauser D. Modulation of DNA repair in vitro after treatment with chemotherapeutic agents by the epidermal growth factor receptor inhibitor gefitinib (ZD1839). Clin Cancer Res 2004; 10: 6476-86
23. Benhar M, Engelberg D, Levitzki A. Cisplatin-induced activation of the EGF receptor. Oncogene 2002; 21: 8723-31
24. Leist M, Jaattela M. Four deaths and a funeral: from caspases to alternative mechanisms. Nat Rev Mol Cell Biol 2001; 2: 589-98
25. Susin SA, Daugas E, Ravagnan L et al. Two distinct pathways leading to nuclear apoptosis. J Exp Med 2000; 192: 571-80
26. Borner C, Monney L. Apoptosis without caspases: an inefficient molecular guillotine? Cell Death Differ 1999; 6: 497-507
27. Kassouf W, Dinney CP, Brown G et al. Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells. Cancer Res 2005; 65: 10524-35
28. Shinohara N, Koyanagi T. Ras signal transduction in carcinogenesis and progression of bladder cancer: molecular target for treatment? Urol Res 2002; 30: 273-81
29. Reddy EP, Reynolds RK, Santos E, Barbacid M. A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene. Nature 1982; 300: 149-52
30. Tabin CJ, Bradley SM, Bargmann CI et al. Mechanism of activation of a human oncogene. Nature 1982; 300: 143-9